On Friday, Neurocrine Biosciences Inc (NBIX) stock saw a modest uptick, ending the day at $143.26 which represents a slight increase of $1.34 or 0.94% from the prior close of $141.92. The stock opened ...

On Thursday, Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently trading at $141.24, with a steady price target of $192.00. The firm ...

On Thursday, Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently trading at $141.24, with a steady price target of $192.00.

Neurocrine Bioscience Inc. said in a federal lawsuit that Spruce Biosciences Inc. is threatening patent litigation over its new rare disease drug Crenessity due to a “desperate need for cash”.

$50,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues regarding potential ...

We may earn a commission through links on our site. Why Trust Us? A GOOD LONG SLEEVE t-shirt is like beer—there are plenty of options that get the job done, but finding truly excellent ones is a ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $121.00. Discover outperforming stocks and invest smarter ...

An End of Phase 2 meeting for NBI-1117568 (NBI-’568, an oral, muscarinic M4 selective agonist) has been completed with the US Food & Drug Administration and Neurocrine reiterated its intentions ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) ...